NCT07225439 2025-11-06Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Case Comprehensive Cancer CenterPhase 1 Not yet recruiting15 enrolled